alexa The Prevention of Cervical Cancer and Other HPV-Related Diseases of the Anogenital Region | Open Access Journals
ISSN: 2157-7420
Journal of Health & Medical Informatics
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

The Prevention of Cervical Cancer and Other HPV-Related Diseases of the Anogenital Region

Balla BC, M.D*

School of Ph.D. Studies, Semmelweis University, Hungary

*Corresponding Author:
Balla BC, M.D.,
School of Ph.D. Studies
Semmelweis University, Hungary
Tel: +3614591500/56184
E-mail: [email protected]

Received Date: March 25, 2017; Accepted Date: March 27, 2017; Published Date: March 30, 2017

Citation: Balla BC (2017) The Prevention of Cervical Cancer and Other HPV-Related Diseases of the Anogenital Region. J Health Med Informat 8:e142. doi: 10.4172/2157-7420.1000e142

Copyright: © 2017 Balla BC. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Health & Medical Informatics

Cervical cancer is the fourth most common cancer in women and the seventh most common cancer, with an estimated amount of 528,000 new cases worldwide in 2012. The majority of cases occur in less developed regions where the estimated 2012 age-standardized incidence rate was more than 30/100,000. These regions include eastern, southern and central Africa and Melanesia. The lowest incidence rates were registered in Australia, New Zealand and western Asia. Concerning mortality, about 266,000 deaths resulted from the malignancy in 2012, from which around 87% occurred in the less developed regions [1].

Cervical cancer is due to HPV infection [2], just like numerous other pathologies of the anogenital region e.g. genital warts, vulvar and vaginal cancer, anal cancer and penile cancer [3]. The virus is transmitted sexually, however transmission is also possible through non-penetrative sexual contact (for example hand to genitals) [4,5] or vertically [6,7].

The estimated average lifetime probability of HPV infection is more than 80% for women and above 90% among men [8]. While HPV infection is mostly acquired in adolescence, two peaks of prevalence had been detected: the first one in the twenties and the second infection peak in middle-age (46-50), however the prevalence varies by virus types and region [9]. Studies have shown that 90% of infections of a particular type clear out within two years [10].

Based on their malignant potential, HPVs can be identified as high-risk and low-risk types. Low-risk HPV types include types 6,11, 42, 43 and 44, while high-risk HPV types include types 16, 18, 31, 33, 34, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 and 70 [11]. In case the infection of a high-risk HPV strain persists, progression to precancerous lesions may occur. HPV-16 and HPV-18 types are responsible for approximately 70% of cervical cancers, while HPV-6 and HPV-11 cause about 90% of genital warts [12].

Currently three prophylactic vaccines have been licensed and are recommended for immunization: the bivalent (types 16 and 18), the quadrivalent (types 6, 11, 16 and 18) and the 9-valent HPV vaccine (types 6, 11, 16, 18, 31, 33, 45, 52 and 58). Vaccination can be started at age 9 and continued through age 26, however it is recommended for routine vaccination at age 11 or 12 [13]. The vaccine can also be beneficial for men, especially for high-risk populations such as men who have sex with men (MSM) [14].

While the prophylactic vaccine may be an effective tool of reducing cervical cancer incidence, the regular attendance of cervical cancer screening (secondary prevention) remains a primordial element of diminishing incidence and mortality.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Article Usage

  • Total views: 295
  • [From(publication date):
    May-2017 - Sep 25, 2017]
  • Breakdown by view type
  • HTML page views : 246
  • PDF downloads :49

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version